115 completed, 41 active not recruiting, 31 recruiting, 27 terminated. 142 Phase 2, 62 Phase 1, 35 Phase 3, 6 Phase 4, 3 Early Phase 1.
Follow Abiraterone Acetate: new trials by email Literature Review of Abiraterone Acetate trials Research Report on Abiraterone Acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Xaluritamig, Abiraterone acetate, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | Amgen | 750 | 2025-11-28 | 2026-10-20 |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer QLC5508, abiraterone acetate, enzalutamide - Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 212 | 2025-11-05 | 2026-06-02 |
| Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer Androgen Receptor Pathway Inhibitors (ARPIs) - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Completed | Ankara Etlik City Hospital | 230 | 2025-10-22 | 2026-10-08 | |
| Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Abiraterone Acetate - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation | Phase 2 | Withdrawn | Qian Qin | 2025-10-01 | 2026-04-08 | |
| Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer QLH12016, abiraterone acetate, enzalutamide - Prostatic Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 50 | 2025-10-01 | 2025-08-05 |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer ASP5541, Prednisone, Prednisolone - Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 218 | 2025-08-19 | 2026-09-03 |
| A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics Darolutamide, Abiraterone acetate, Enzalutamide - Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer | Recruiting | Bayer | 1400 | 2025-07-22 | 2026-07-07 | |
| Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer Abiraterone acetate, Dexamethasone, Metronidazole - Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 58 | 2025-02-13 | 2026-02-19 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-10-02 |
| REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial Abiraterone Acetate, Bicalutamide, Biospecimen Collection - Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Recruiting | Emory University | 72 | 2025-01-31 | 2026-02-24 |
| Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT, Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT - Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer) | Phase 3 | Not yet recruiting | Ding-Wei Ye | 400 | 2025-01-30 | 2025-01-10 |
| Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate Cancer abiraterone acetate tablets (II) - Diagnosed With Metastatic Prostate Cancer | Active not recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 3000 | 2025-01-08 | 2026-07-23 | |
| PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer Enzalutamide, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets - Prostate Cancer, Metastatic Cancer | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 152 | 2024-12-20 | 2025-03-12 | |
| Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C) - High Risk Prostate Carcinoma, Prostate Cancer | Phase 2 | Active not recruiting | Ivan de Kouchkovsky, MD | 32 | 2024-12-09 | 2026-09-04 |
| Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone. - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Jianbin Bi | 40 | 2024-11-27 | 2025-05-14 |
| M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) M9466, Tuvusertib, Abiraterone acetate - Advanced Solid Tumor | Phase 1 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 60 | 2024-08-07 | 2026-09-09 |
| Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer. Dalpicilib, Abiraterone Acetate (II), Androgen Deprivation Therapy - The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer | Phase 2 | Not yet recruiting | Qilu Hospital of Shandong University | 43 | 2024-07-31 | 2024-07-15 |
Showing 20 of 249. Sign in to see all of them.
Prostatic Neoplasms (174) · Neoplasm Metastasis (13) · Prostatic Neoplasms, Castration-Resistant (12) · Breast Neoplasms (6) · Neoplasms (5) · Genital Neoplasms, Male (3) · Urogenital Neoplasms (3) · Adenocarcinoma (2) · Adrenal Hyperplasia, Congenital (2) · Carcinoma, Non-Small-Cell Lung (2) · Genital Diseases, Male (2) · Adrenocortical Carcinoma (1) · Cancer Pain (1) · Carcinoma, Transitional Cell (1) · Cognitive Dysfunction (1)
Janssen Research & Development, LLC (29) · M.D. Anderson Cancer Center (10) · AstraZeneca (9) · Cougar Biotechnology, Inc. (7) · Dana-Farber Cancer Institute (6) · University of Washington (6) · Pfizer (5) · Jiangsu HengRui Medicine Co., Ltd. (4) · Mayo Clinic (4) · Memorial Sloan Kettering Cancer Center (4) · Merck Sharp & Dohme LLC (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Aragon Pharmaceuticals, Inc. (3) · Astellas Pharma Global Development, Inc. (3) · Bayer (3)
United States (161) · United Kingdom (44) · Spain (38) · Canada (36) · China (35) · France (32) · Australia (29) · Belgium (27) · Netherlands (25) · Germany (24) · Italy (24) · South Korea (24) · Brazil (18) · Japan (18) · Taiwan (16)
Cougar Biotechnology, Inc. Clinical Trial (5) · Mary-Ellen Taplin, MD (3) · Michael Schweizer (3) · Christopher Logothetis (2) · Christopher Logothetis, MD (2) · Daniel George, MD (2) · Fred Saad, MD (2) · Jingsong Zhang, M.D., Ph.D. (2) · Kim N Chi, MD (2)
PMID 40016438, PMID 21612468, PMID 21802835, PMID 22747660, PMID 24787968, PMID 25829400, PMID 26609008, PMID 32923850, PMID 36898948, PMID 39074346, PMID 41732008, PMID 42186347, PMID 42286315, PMID 11745214, PMID 14985252, PMID 16172198, PMID 16580903, PMID 16670169, PMID 18309951, PMID 18619560, PMID 18990168, PMID 19223900, PMID 19500762, PMID 21220434, PMID 22452894, PMID 22995653, PMID 22997446, PMID 23142059, PMID 23228172, PMID 23470964, PMID 23816964, PMID 23973186, PMID 24075621, PMID 24099659, PMID 24210085, PMID 24268504, PMID 24374856, PMID 24647231, PMID 25091040, PMID 25242048, PMID 25320358, PMID 25593303, PMID 25601341, PMID 25624432, PMID 25800753, PMID 25985882, PMID 26278649, PMID 26343110, PMID 26353009, PMID 26504153
2023 (14), 2016 (7), 2017 (4), 2014 (3), P30CA015704 (3), 2018 (2), 2019 (2), P50CA097186 (2), U10CA180820 (2), 2004 (1), 2008 (1), I01CX002517 (1), N01CM00038 (1), N01CM00039 (1), N01CM00071 (1)